Helen H. Hobbs is an Investigator of the Howard Hughes Medical Institute at the University of Texas Southwestern Medical Center (UTSW) in Dallas, Texas. After attending Stanford University and Case Western Reserve Medical School, she trained in internal medicine and endocrinology at Columbia-Presbyterian and UTSW. She joined the UTSW faculty in 1987 where she is Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development. Together with Jonathan Cohen, she has used human genetics to identify sequence variations in genes with large effects on plasma levels of LDL-cholesterol (ABCG5/ABCG8, LDLRAP, PCSK9, NPC1L1, ANGPTL3) and triglyceride (ANGPTL3,-4,-8). More recently, she discovered the two most impactful genetic risk factors for fatty liver disease (PNPLA3, TM6SF2). Gene identification is the starting point for studies that have elucidated pathways and processes altered by the defective genes she has identified. She is a member of the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, and the National Academy of Sciences. She is recipient of The Breakthrough Prize in Life Sciences (2016) and the Harrington Prize for Innovation in Medicine (2018).
Helen H. Hobbs, MD